Cargando…
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage innate immune effectors through interactions mediated by their fragment crystallizable (Fc) domain. By delivering Fc-Fc gamma receptor (FcγR) and Fc-C1q interactions, mAb are able to link exquisite specificity to po...
Autores principales: | Liu, Rena, Oldham, Robert J., Teal, Emma, Beers, Stephen A., Cragg, Mark S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709126/ https://www.ncbi.nlm.nih.gov/pubmed/33212886 http://dx.doi.org/10.3390/antib9040064 |
Ejemplares similares
-
IgG Fc engineering to modulate antibody effector functions
por: Wang, Xinhua, et al.
Publicado: (2017) -
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020) -
Fc-engineered antibodies with immune effector functions completely abolished
por: Wilkinson, Ian, et al.
Publicado: (2021) -
Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
por: Escobar-Cabrera, Eric, et al.
Publicado: (2017) -
Engineered Fc-glycosylation switch to eliminate antibody effector function
por: Zhou, Qun, et al.
Publicado: (2020)